Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ritlecitinib (PF-06651600) in Healthy Japanese Subjects
NCT03232905Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing PF-06651600 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs, Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters at Day 10 and 3 more. Started Aug 2017; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03232905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232905.